We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

SYSMEX-EUROPA

Sysmex Europe designs and produces laboratory and hematology diagnostic solutions, including instruments, reagents, c... read more Featured Products: More products

Download Mobile App




Events

17 Jun 2026 - 19 Jun 2026
25 Jun 2026 - 27 Jun 2026
05 Oct 2026 - 06 Oct 2026

Automated Urine Analyzer Offers Fast, Sensitive and Precise AST in Near-Patient Settings

By HospiMedica International staff writers
Posted on 26 Apr 2023

Urinary tract infections (UTIs) are highly prevalent infectious diseases, impacting an estimated 150 million people worldwide. More...

Typically, these infections are treated with antimicrobial drugs. To determine the appropriate medication, healthcare professionals must conduct bacteria identification tests and drug susceptibility tests alongside clinical findings. However, these tests often take days to complete, making it challenging to prescribe the right antimicrobial drugs during the first consultation. Consequently, this can lead to the prescription of improper medications and contribute to the development of antimicrobial resistance.

The PA-100 AST System from Sysmex Europe SE (Norderstedt, Germany) is an innovative automated urine analyzer that expedites antimicrobial susceptibility testing (AST) at the point of care. By combining phase contrast microscopy and nanofluidics, the system generates antibiograms at the point of care. The cutting-edge nanofluidics-based technology ensures exceptional diagnostic performance. User-friendly and efficient, the PA-100 AST System can determine bacterial growth and AST in under an hour, with results conforming to EUCAST standards.

Employing lab-on-a-chip technology, the PA-100 AST System rapidly and automatically analyzes urine samples, optimizing workflow and providing results during a patient's initial visit to the physician. This breakthrough technology brings diagnostics to outpatient clinics, supporting evidence-based medication where extensive antibiotic prescriptions are common. By facilitating antibiotic prescription decisions in less than an hour, the system helps circumvent empirical treatment and curtail the spread of antimicrobial resistance.

Related Links:
Sysmex Europe SE 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Rapid Sepsis Test
SeptiCyte RAPID
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Coredio’s CPSE is a a software-as-a-medical-device platform designed for use with consumer smartwatches and standard blood pressure cuffs in clinical and home settings under physician supervision (Photo courtesy of Coredio)

AI Platform Supports Noninvasive Remote Hemodynamic Monitoring in Heart Failure

Heart failure remains a leading cause of hospitalization in adults over 65, affecting more than 6.7 million people in the U.S. Clinicians often lose visibility into hemodynamic deterioration once patients... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.